Loading…

Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence

Background. R0 minor parenchyma-sparing hepatectomy (PSH) is feasible for colorectal liver metastases (CRLM) in contact with hepatic veins (HV) at hepatocaval confluence since HV can be reconstructed, but in the case of contact with the first-order glissonean pedicle (GP), major hepatectomy is manda...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-09, Vol.15 (19), p.4683
Main Authors: Urbani, Lucio, Roffi, Nicolò, Moretto, Roberto, Signori, Stefano, Balestri, Riccardo, Rossi, Elisabetta, Colombatto, Piero, Licitra, Gabriella, Leoni, Chiara, Martinelli, Rita, Meiattini, Daniele Anacleto, Bonistalli, Emidio, Borelli, Beatrice, Antoniotti, Carlotta, Masi, Gianluca, Rossini, Daniele, Boraschi, Piero, Donati, Francescamaria, Della Pina, Maria Clotilde, Lunardi, Alessandro, Daviddi, Francesco, Crocetti, Laura, Tonerini, Michele, Gigoni, Roberto, Quilici, Francesca, Gaeta, Raffaele, Turco, Francesca, Paolicchi, Adriana, Volterrani, Duccio, Nardini, Vincenzo, Buccianti, Piero, Forfori, Francesco, Puccini, Marco, Cremolini, Chiara
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. R0 minor parenchyma-sparing hepatectomy (PSH) is feasible for colorectal liver metastases (CRLM) in contact with hepatic veins (HV) at hepatocaval confluence since HV can be reconstructed, but in the case of contact with the first-order glissonean pedicle (GP), major hepatectomy is mandatory. To pursue an R0 parenchyma-sparing policy, we proposed vessel-guided mesohepatectomy for liver partition (MLP) and eventually combination with liver augmentation techniques for staged major PSH. Methods. We analyzed 15 consecutive vessel-guided MLPs for CRLM at the hepatocaval confluence. Patients had a median of 11 (range: 0–67) lesions with a median diameter of 3.5 cm (range: 0.0–8.0), bilateral in 73% of cases. Results. Grade IIIb or more complications occurred in 13%, median hospital stay was 14 (range: 6–62) days, 90-day mortality was 0%. After a median follow-up of 17.5 months, 1-year OS and RFS were 92% and 62%. In nine (64%) patients, MLP was combined with portal vein embolization (PVE) or ALPPS to perform staged R0 major PSH. Future liver remnant (FLR) volume increased from a median of 15% (range: 7–20%) up to 41% (range: 37–69%). Super-selective PVE was performed in three (33%) patients and enhanced ALPPS (e-ALPPS) in six (66%). In two e-ALPPS an intermediate stage of deportalized liver PSH was necessary to achieve adequate FLR volume. Conclusions. Vessel-guided MLP may transform the liver in a paired organ. In selected cases of multiple bilobar CRLM, to guarantee oncological radicality (R0), major PSH is feasible combining advanced surgical parenchyma sparing with liver augmentation techniques when FLR volume is insufficient.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15194683